Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Deferred Revenue (2016 - 2018)

ImmunityBio (IBRX) has disclosed Current Deferred Revenue for 5 consecutive years, with $598000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Current Deferred Revenue rose 15.0% to $598000.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $598000.0, a 15.0% increase, with the full-year FY2018 number at $598000.0, up 15.0% from a year prior.
  • Current Deferred Revenue was $598000.0 for Q4 2018 at ImmunityBio, up from $577000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $598000.0 in Q4 2018 to a low of $5000.0 in Q4 2015.
  • A 5-year average of $407538.5 and a median of $501000.0 in 2017 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: tumbled 99.04% in 2015, then skyrocketed 3840.0% in 2016.
  • ImmunityBio's Current Deferred Revenue stood at $521000.0 in 2014, then crashed by 99.04% to $5000.0 in 2015, then surged by 3840.0% to $197000.0 in 2016, then surged by 163.96% to $520000.0 in 2017, then grew by 15.0% to $598000.0 in 2018.
  • Per Business Quant, the three most recent readings for IBRX's Current Deferred Revenue are $598000.0 (Q4 2018), $577000.0 (Q3 2018), and $558000.0 (Q2 2018).